Glucocorticoid induced osteoporosis

References

• Overman RA, Yeh JY, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective. Arthritis Care Res. 2013;65(2):294–298.
   PubMed Web of Science ®Google Scholar
• Curtis JR, Westfall AO, Allison J, et al. Population‐based assessment of adverse events associated with long‐term glucocorticoid use. Arthritis Care Res. 2006;55(3):420–426.
   Web of Science ®Google Scholar
• Angeli A, Guglielmi G, Dovio A, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone. 2006;39(2):253–259.
   PubMed Web of Science ®Google Scholar
• Buckley L, Guyatt G, Fink HA, et al. 2017 American college of rheumatology guideline for the prevention and treatment of glucocorticoid‐induced osteoporosis. Arthritis Rheumatol. 2017;69(8):1521–1537.
   PubMed Web of Science ®Google Scholar
• Canalis E, Mazziotti G, Giustina A, et al. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18(10):1319–1328.
   PubMed Web of Science ®Google Scholar
• Canalis E. Mechanisms of glucocorticoid action in bone. Curr Osteoporos Rep. 2005;3(3):98–102.
   PubMedGoogle Scholar
• Teitelbaum SL. Bone resorption by osteoclasts. Science. 2000;289(5484):1504–1508.
   PubMed Web of Science ®Google Scholar
• Smith E, Redman RA, Logg CR, et al. Glucocorticoids inhibit developmental stage-specific osteoblast cell cycle dissociation of cyclin A-cyclin-dependent kinase 2 from E2F4-p130 complexes. J Biol Chem. 2000;275(26):19992–20001.
   PubMed Web of Science ®Google Scholar
• Delany AM, Gabbitas BY, Canalis E. Cortisol downregulates osteoblast α1 (I) procollagen mRNA by transcriptional and posttranscriptional mechanisms. J Cell Biochem. 1995;57(3):488–494.
   PubMed Web of Science ®Google Scholar
• Ishida Y, Heersche JN. Glucocorticoid‐induced osteoporosis: both in vivo and in vitro concentrations of glucocorticoids higher than physiological levels attenuate osteoblast differentiation. J Bone Miner Res. 1998;13(12):1822–1826.
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Jilka RL, Parfitt AM, et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest. 1998;102(2):274–282.
   PubMed Web of Science ®Google Scholar
• Amiche MA, Albaum JM, Tadrous M, et al. Fracture risk in oral glucocorticoid users: a Bayesian meta-regression leveraging control arms of osteoporosis clinical trials. Osteoporos Int. 2016;27(5):1709–1718.
   PubMed Web of Science ®Google Scholar
• LoCascio V, Bonucci E, Imbimbo B, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Miner. 1990;8(1):39–51.
   PubMedGoogle Scholar
• Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res. 2000;15(6):993–1000.
   PubMed Web of Science ®Google Scholar
• Stanbury RM, Graham EM. Systemic corticosteroid therapy – side effects and their management. Br J Ophthalmol. 1998;82(6):704–708.
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HG, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int. 2002;13(10):777–787.
   PubMed Web of Science ®Google Scholar
• Bultink IE, Lems WF, Kostense PJ, et al. Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum. 2005;52(7):2044–2050.
   PubMed Web of Science ®Google Scholar
• Ventura A, Brunetti G, Colucci S, et al. Glucocorticoid-induced osteoporosis in children with 21-hydroxylase deficiency. Biomed Res Int. 2013;2013.
   Web of Science ®Google Scholar
• Faienza MF, Brunetti G, Colucci S, et al. Osteoclastogenesis in children with 21-hydroxylase deficiency on long-term glucocorticoid therapy: the role of receptor activator of nuclear factor-κB ligand/osteoprotegerin imbalance. J Clin Endocrinol Metab. 2009;94(7):2269–2276.
   PubMed Web of Science ®Google Scholar
• Nanes MS, Kallen CB. Clinical assessment of fracture risk and novel therapeutic strategies to combat osteoporosis. Fertil Steril. 2009;92(2):403–412.
   PubMed Web of Science ®Google Scholar
• Briot K, Roux C. Ostéoporose cortico-induite. Rev Med Interne. 2013;34(5):315–323.
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, et al. A meta‐analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004;19(6):893–899.
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Ishitani K, Ohta H. Usefulness of FRAX and future issues in women’s health. Clin Calcium. 2009;19(12):1742–1748.
   PubMedGoogle Scholar
• Kanis JA, Johansson H, Oden A, et al. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int. 2011;22(3):809–816.
   PubMed Web of Science ®Google Scholar
• Fraser LA, Adachi JD. Glucocorticoid-induced osteoporosis: treatment update and review. Ther Adv Musculoskelet Dis. 2009;1(2):71–85.
   PubMedGoogle Scholar
• Gennari C. Calcium and vitamin D nutrition and bone disease of the elderly. Public Health Nutr. 2001;4(2b):547–559.
   PubMedGoogle Scholar
• Adachi JD, Bensen WG, Bianchi F, et al. Vitamin D and calcium in the prevention of corticosteroid induced osteoporosis: a 3 year followup. J Rheumatol. 1996;23(6):995–1000.
   PubMed Web of Science ®Google Scholar
• Amin S, LaValley MP, Simms RW, et al. The role of vitamin D in corticosteroid‐induced osteoporosis: a meta‐analytic approach. Arthritis Rheum. 1999;42(8):1740–1751.
   PubMed Web of Science ®Google Scholar
• Amin S, Lavalley MP, Simms RW, et al. The comparative efficacy of drug therapies used for the management of corticosteroid‐induced osteoporosis: a meta‐regression. J Bone Miner Res. 2002;17(8):1512–1526.
   PubMed Web of Science ®Google Scholar
• Pavone V, Testa G, Giardina S, et al. Pharmacological therapy of osteoporosis: a systematic current review of literature. Front Pharmacol. 2017;8:803.
   PubMed Web of Science ®Google Scholar
• Van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int. 2006;79(3):129–137.
   PubMed Web of Science ®Google Scholar
• Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med. 1998;339(5):292–299.
   PubMed Web of Science ®Google Scholar
• Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid‐induced bone loss: a twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study. Arthritis Rheum. 1999;42(11):2309–2318.
   PubMed Web of Science ®Google Scholar
• Reid DM, Hughes RA, Laan RF, et al. Efficacy and safety of daily risedronate in the treatment of corticosteroid‐induced osteoporosis in men and women: a randomized trial. J Bone Miner Res. 2000;15(6):1006–1013.
   PubMed Web of Science ®Google Scholar
• Reid DM, Hosking D, Kendler D, et al. A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24‐month results from FACTS‐International. Int J Clin Pract. 2008;62(4):575–584.
   PubMed Web of Science ®Google Scholar
• Amiche MA, Lévesque LE, Gomes T, et al. Effectiveness of oral bisphosphonates in reducing fracture risk among oral glucocorticoid users: three matched cohort analyses. J Bone Miner Res. 2018;33(3):419–429.
   PubMed Web of Science ®Google Scholar
• Wang YK, Zhang YM, Qin SQ, et al. Effects of alendronate for treatment of glucocorticoid-induced osteoporosis: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97:42.
   Web of Science ®Google Scholar
• Briesacher BA, Andrade SE, Yood RA, et al. Consequences of poor compliance with bisphosphonates. Bone. 2007;41(5):882–887.
   PubMed Web of Science ®Google Scholar
• Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009;373(9671):1253–1263.
   PubMed Web of Science ®Google Scholar
• Coskun IB. Denosumab in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int. 2018;38(11):1975-1984.
   Web of Science ®Google Scholar
• Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018;6(6):445–454.
   PubMed Web of Science ®Google Scholar
• Mok CC, Ho LY, Ma KM. Switching of oral bisphosphonates to denosumab in chronic glucocorticoid users: a 12-month randomized controlled trial. Bone. 2015;75:222–228.
   PubMed Web of Science ®Google Scholar
• Jilka RL, O’Brien CA, Ali AA, et al. Intermittent PTH stimulates periosteal bone formation by actions on post-mitotic preosteoblasts. Bone. 2009;44(2):275–286.
   PubMed Web of Science ®Google Scholar
• Lane NE, Sanchez S, Modin GW, et al. Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial. J Clin Invest. 1998;102(8):1627–1633.
   PubMed Web of Science ®Google Scholar
• Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357(20):2028–2039.
   PubMed Web of Science ®Google Scholar